Astellas’ Cresemba Review: Orphan Population With Unmet Need Vs. Limited Efficacy Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anti-Infective Drugs Advisory Committee will vote on whether efficacy and safety evidence support approval of Astellas’ antifungal isavuconazonium for two indications, one of which has no controlled data.